|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1998-3-31
|
|
pubmed:abstractText |
The antiviral activity of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil (L-FMAU), a novel L-nucleoside analog of thymidine known to be an inhibitor of hepatitis B virus (HBV) replication in hepatoma cells (2.2.1.5 cell line), was evaluated in the duck HBV (DHBV) model. Short-term oral administration (5 days) of L-FMAU (40 mg/kg of body weight/day) to experimentally infected ducklings induced a significant decrease in the level of viremia. This antiviral effect was sustained in animals when therapy was prolonged for 8 days. The histological study showed no evidence of liver toxicity in the L-FMAU-treated group. By contrast, microvesicular steatosis was found in the livers of dideoxycytidine-treated animals. L-FMAU administration in primary duck hepatocyte cultures infected with DHBV induced a dose-dependent inhibition of both virion release in culture supernatants and intracellular viral DNA synthesis, without clearance of viral covalently closed circular DNA. By using a cell-free system for the expression of an enzymatically active DHBV reverse transcriptase, it was shown that L-FMAU triphosphate exhibits an inhibitory effect on the incorporation of dAMP in the viral DNA primer. Thus, our data demonstrate that L-FMAU inhibits DHBV replication in vitro and in vivo. Long-term administration of L-FMAU for the eradication of viral infection in animal models of HBV infection should be evaluated.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-1629711,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-1718087,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-1738197,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-2155510,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-2334160,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-2335817,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-2647612,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-2745424,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-3512855,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7463557,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7504742,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7510440,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7525986,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7539509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7565947,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7565951,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7625783,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7786007,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7860738,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7966625,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-7989703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8031035,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8289335,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8294097,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8622980,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8726039,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8764034,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8781347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8781348,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8834884,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8834889,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8834896,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-8988118,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-9011789,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9527788-9224504
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0066-4804
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
369-76
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9527788-Administration, Oral,
pubmed-meshheading:9527788-Animals,
pubmed-meshheading:9527788-Antiviral Agents,
pubmed-meshheading:9527788-Arabinofuranosyluracil,
pubmed-meshheading:9527788-DNA, Viral,
pubmed-meshheading:9527788-Ducks,
pubmed-meshheading:9527788-Hepadnaviridae Infections,
pubmed-meshheading:9527788-Hepatitis B Virus, Duck,
pubmed-meshheading:9527788-Liver,
pubmed-meshheading:9527788-Virus Replication
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.
|
|
pubmed:affiliation |
INSERM U271, Lyon, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
